Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:20 PM
Ignite Modification Date:
2026-03-26 @ 3:20 PM
NCT ID:
NCT07374120
Eligibility Criteria:
Inclusion criteria:
1. Patients whose data were accessible for research purposes during the study observation period.
2. Patients diagnosed with CML-CP at first recorded diagnosis of CML.
3. Patients ≥ 18 years of age at first recorded diagnosis of CML.
4. Patients who initiated qualifying 1L therapy for CML-CP during the study identification period. Qualifying 1L therapy treatments consisted of imatinib, dasatinib, bosutinib, or nilotinib as monotherapy.
5. Patients with ≥1 visit within The US Oncology Network practices following initiation of 1L therapy and through the end of the study observation period.
Exclusion criteria:
1. Patients enrolled in interventional clinical trials during the study observation period.
2. Patients who received any systemic treatment indicated for another primary cancer during the study observation period.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07374120
Study Brief:
Protocol Section:
NCT07374120